(Q70706973)
Statements
Maintained intraocular pressure reduction with once-a-day application of a new prostaglandin F2 alpha analogue (PhXA41). An in-hospital, placebo-controlled study (English)
P Rácz
M R Ruzsonyi
Z T Nagy
scientific article published on 01 May 1993